Home
JournalsCollections
For Authors For Reviewers For Editorial Board Members
Article Processing Charges Open Access
Ethics Advertising Policy
Editorial Policy Resource Center
Company Information Contact Us Membership Collaborators Partners
OPEN ACCESS

Research progress in the use of bifidobacteria for the treatment of colorectal cancer

  • Yu-Ting Zhao1,
  • Zhi-Hui Cai2,* and
  • Yu-Chen Yang2
Gastroenterology & Hepatology Research   2022;4(3):16

doi: 10.53388/ghr2022-09-058

Published online:

 Author information

Citation: Zhao YT, Cai ZH, Yang YC. Research progress in the use of bifidobacteria for the treatment of colorectal cancer. Gastroenterol & Hepatol Res. 2022;4(3):16. doi: 10.53388/ghr2022-09-058.

Abstract

Colorectal cancer has high morbidity and mortality rates; therefore, developing new therapeutic drugs and methods for it is crucial. There is increasing evidence that intestinal flora plays a vital role in maintaining intestinal homeostasis and therefore, in the development of colorectal cancer. As such, therapeutic approaches using probiotics such as Bifidobacterium lactis to regulate intestinal flora are expected to represent a new treatment strategy for colorectal cancer. This article introduces and compares the development status of conventional therapies for colorectal cancer, primarily targeted therapy and immunotherapy, the relationship between intestinal flora and colorectal cancer, and the research and application of Bifidobacterium bifidum in colorectal cancer treatment to provide a reference for its clinical application.

Keywords

colorectal cancer treatment, intestinal flora, bifidobacteria

About this Article

Cite this article
Zhao YT, Cai ZH, Yang YC. Research progress in the use of bifidobacteria for the treatment of colorectal cancer. Gastroenterol & Hepatol Res. 2022;4(3):16. doi: 10.53388/ghr2022-09-058.
Copy Export to RIS Export to EndNote
Article History
Received Revised Accepted Published
September 29, 2022
DOI http://dx.doi.org/10.53388/ghr2022-09-058